Jiang JingSi, Li XiaoGang, Mi YuXin, Wang YiYing, Heng YanXi, Li ZhiWen, Deng Min
Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
Department of Neurology, Peking University Third Hospital, Beijing, China.
Neurodegener Dis Manag. 2025 Apr-Jun;15(2-3):77-87. doi: 10.1080/17582024.2025.2488235. Epub 2025 Apr 4.
This study aimed to evaluate the effects of riluzole on survival and changes in ALS Functional Rating Scale (ALSFRS) among Chinese patients with Amyotrophic Lateral Sclerosis (ALS).
PATIENTS & METHODS: Propensity score matching was used to balance baseline variables between the riluzole group ( = 238) and control group ( = 454). Survival was analyzed using Kaplan - Meier curves and Cox regression, while multivariable linear regression assessed ALSFRS changes at 6 and 12 months. Subgroup analyses were conducted to identify potential responders.
Riluzole did not significantly improve survival ( = 0.478) or ALSFRS changes at 6 months ( = 0.380) or 12 months ( = 0.175). Subgroup analyses revealed no survival benefit in any subgroup, and further stratification showed inconsistent adverse effects on ALSFRS scores.
Riluzole neither prolonged survival nor slowed functional decline in Chinese ALS patients, with no subgroup demonstrating a better response.
本研究旨在评估利鲁唑对中国肌萎缩侧索硬化症（ALS）患者生存率及肌萎缩侧索硬化功能评定量表（ALSFRS）变化的影响。
采用倾向得分匹配法平衡利鲁唑组（n = 238）和对照组（n = 454）之间的基线变量。使用Kaplan - Meier曲线和Cox回归分析生存率，同时采用多变量线性回归评估6个月和12个月时ALSFRS的变化。进行亚组分析以确定潜在的反应者。
利鲁唑未显著改善生存率（P = 0.478），也未显著改善6个月时（P = 0.380）或12个月时（P = 0.175）的ALSFRS变化。亚组分析显示任何亚组均未获得生存益处，进一步分层显示对ALSFRS评分的不良反应不一致。
利鲁唑既未延长中国ALS患者的生存期，也未减缓其功能衰退，没有亚组显示出更好的反应。
